EP13.03-15 Efficacy of First-Line Tislelizumab Plus Etoposide and Carboplatin in ES-SCLC

Small-cell lung cancer (SCLC) is a malignancy which exhibits a high level of aggression and has the characteristics of growing rapidly and metastasizing early. The standard first-line treatment strategy for ES-SCLC is 4-6 cycles of cisplatin-based doublet chemotherapy with immunotherapy. Tislelizumab is a humanized monoclonal antibody against PD-1 and has been approved for a number of indications excluding ES-SCLC. Our study aims to evaluate the efficacy and safety of tislelizumab plus etoposide and carboplatin as front-line setting in ES-SCLC.